Allos raises £3.7m in seed financing led by Oxford Science Enterprises to expand its causal artificial intelligence platform.
Oxford Science Enterprises led the seed round to support expansion across formulation development and data science.
Allos applies causal artificial intelligence to commercialise a platform for the end-to-end reformulation of complex generic drugs and next-generation medicines. The company helps developers modernise legacy pharmaceutical assets and reduce clinical uncertainty.
Allos has secured £3.7m in seed financing to accelerate the commercialisation of its causal artificial intelligence platform. Oxford Science Enterprises led the round, with participation from Habico Invest and Berkeley SKYDECK.
The funding will support the company as it expands its team across formulation development and data science. Allos focuses on hard-to-genericize small-molecule medicines, aiming to make specialty treatments easier to take and economically viable for manufacturers.
From the founder
"For decades, the pharmaceutical system has treated approval as the finish line, even though for patients it marks the start of a much longer journey."
Aditya Iyer
CEO and co-founder at Allos
Investor perspective
"Most AI efforts in drug development focus on discovering new molecules, but that’s not where the near-term opportunity lies."
Joel Schoppig
Health Tech Investment Principal, Oxford Science Enterprises
Use of funds
- 01Grow the team
- 02Continue product development
